NCT03353831 2025-04-06
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
AGO Research GmbH
Phase 3 Completed
Clinical Trials
11 trialsNCT03206047 2025-03-13
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02891824 2025-02-11
ATALANTE
ARCAGY/ GINECO GROUP
Phase 3 Completed
NCT02876510 2025-02-04
ACTolog
Immatics US, Inc.
Phase 1 Completed
NCT03598270 2024-08-30
ANITA
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Completed
NCT03695380 2023-08-14
A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT03073525 2023-04-05
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Gradalis, Inc.
Phase 2 Completed
NCT02659384 2023-03-14
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03038100 2023-02-17
IMagyn050
Hoffmann-La Roche
Phase 3 Completed
NCT02914470 2021-10-19
PROLOG
The Netherlands Cancer Institute
Phase 1 Completed
NCT03394885 2021-08-12
AdORN
Duke University
Phase 1/2 Completed